Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.
The anti-apoptotic protein Mcl-1 plays a major role in multiple myeloma (MM) cell survival as well as bortezomib- and microenvironmental forms of drug resistance in this disease. Consequently, there is a critical need for strategies capable of targeting Mcl-1-dependent drug resistance in MM. The pre...
Main Authors: | Xin-Yan Pei, Yun Dai, Jessica Felthousen, Shuang Chen, Yukie Takabatake, Liang Zhou, Leena E Youssefian, Michael W Sanderson, Wesley W Bodie, Lora B Kramer, Robert Z Orlowski, Steven Grant |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3942309?pdf=render |
Similar Items
-
MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
by: Alcon, C., et al.
Published: (2022) -
Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
by: Omar S. Al-Odat, et al.
Published: (2021-07-01) -
miR-107 activates ATR/Chk1 pathway and suppress cervical cancer invasion by targeting MCL1.
by: Chengyan Zhou, et al.
Published: (2014-01-01) -
Erratum: Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
by: Frontiers Production Office
Published: (2021-08-01) -
Downregulation of CDC20 Increases Radiosensitivity through Mcl-1/p-Chk1-Mediated DNA Damage and Apoptosis in Tumor Cells
by: Yang Gao, et al.
Published: (2020-09-01)